Investigational drug · Phase 3
AZD0901
Also called: Sonesitatug vedotin, CMG901
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
6 still active
All registered trials
6
Any phase or sponsor naming "AZD0901"
First trial start
2023
Jan 16, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD0901", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
- Gastroesophageal Junction Cancer
- Gastroesophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Cancer
- Biliary Tract Cancer
- Pancreatic Ductal Adenocarcinoma
Approved drugs for the same conditions: Pancreatic cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD0901" as an intervention, largest first.
- Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07431281 · 2,130 participants (planned) · Start Feb 3, 2026 · Primary completion Aug 16, 2029
Drug: Sonesitatug vedotin; Rilvegostomig and 6 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 314 sites in all
- AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06346392 · 594 participants · Start Mar 4, 2024 · Primary completion May 31, 2026
Drug: AZD0901; AZD0901 and 6 more · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: Mobile, Alabama; Tucson, Arizona; Duarte, California · 158 sites in all
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06219941 · 226 participants (planned) · Start Dec 13, 2023 · Primary completion Nov 17, 2026
Drug: AZD0901; 5-Fluorouracil and 5 more · For: Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer and 1 more
Sites: Orange, California; Palo Alto, California; Santa Rosa, California · 52 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05702229 · 163 participants (planned) · Start Jan 16, 2023 · Primary completion Nov 30, 2027
Drug: Rilvegostomig; Volrustomig and 5 more · For: Gastric Cancer
Sites: Los Angeles, California; Baton Rouge, Louisiana; Grand Rapids, Michigan · 44 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07069712 · 100 participants (planned) · Start Jul 17, 2025 · Primary completion Nov 9, 2027
Drug: Sonesitatug Vedotin; Rilvegostomig and 5 more · For: Gastroesophageal Adenocarcinoma
Sites: Newark, Delaware; Washington D.C., District of Columbia; Fairway, Kansas · 70 sites in all
- A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2Active, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT07143604 · 33 participants · Start Aug 29, 2025 · Primary completion Aug 14, 2026
Drug: AZD0901 · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: Chelyabinsk, Russia; Krasnoyarsk, Russia; Kuzmolovskiy, Russia · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antibodies to watch in 2026.
Crescioli S, Kaplon H, Chenoweth A, et al. · MAbs 2026
- CLDN18.2 ADCs "A Real Step Forward" for Stomach Cancer.
· Cancer Discov 2026
- CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapy.
Katoh M, Katoh M · Front Mol Med 2026
- Antibody-Drug Conjugates in the Treatment of Esophageal Cancer.
Wu D, Chen W, Zhao Q, et al. · Curr Treat Options Oncol 2026
- Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules.
Katoh M, Loriot Y, Nakayama I, et al. · Front Mol Med 2025
- Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial.
Ruan DY, Liu FR, Wei XL, et al. · Lancet Oncol 2025
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.